Student or educator? Sign up with your school email and get 6 months of Pro free.
Cited by 288

The DOI matches its Crossref record; 55 of the 55 references it cites were found in a registry or an index.

Phase I Trial of Temozolomide Plus O6-Benzylguanine for Patients With Recurrent or Progressive Malignant Glioma

Open access
Quinn, Jennifer A., Desjardins, Annick, Weingart, Jon, Brem, Henry, Dolan, M. Eileen, Delaney, Shannon M., Vredenburgh, James, Rich, Jeremy, Friedman, Allan H., Reardon, David A., Sampson, John H., Pegg, Anthony E., Moschel, Robert C., Birch, Robert, McLendon, Roger E., Provenzale, James M., Gururangan, Sridharan, Dancey, Janet E., Maxwell, Jill, Tourt-Uhlig, Sandra, Herndon, James E., Bigner, Darell D., Friedman, Henry S.·2005·Journal of Clinical Oncology

Abstract

Purpose: We conducted a two-phase clinical trial in patients with progressive malignant glioma (MG). The first phase of this trial was designed to determine the dose of O 6-BG effective in producing complete depletion of tumor AGT activity for 48 hours. The second phase of the trial was designed to define the maximum tolerated dose (MTD) of a single dose of temozolomide when combined with O 6-BG. In addition, plasma concentrations of O 6-BG and O 6-benzyl-8-oxoguanine were evaluated after O 6-BG. Patients and Methods: For our first phase of the clinical trial, patients were scheduled to undergo craniotomy for AGT determination after receiving a 1-hour O 6-BG infusion at 120 mg/m 2 followed by a continuous infusion at an initial dose of 30 mg/m 2/d for 48 hours. The dose of the continuous infusion of O 6-BG escalated until tumor AGT was depleted. Once the O 6-BG dose was established a separate group of patients was enrolled in the second phase of clinical trial, in which temozolomide, administered as a single dose at the end of the 1-hour O 6-BG infusion, was escalated until the MTD was determined. Results: The O 6-BG dose found to be effective in depleting tumor AGT activity at 48 hours was an IV bolus of 120 mg/m 2 over 1 hour followed by a continuous infusion of 30 mg/m 2/d for 48 hours. On enrolling 38 patients in six dose levels of temozolomide, the MTD was established at 472 mg/m 2 with dose-limiting toxicities limited to myelosuppression. Conclusion: This study provides the foundation for a phase II trial of O 6-BG plus temozolomide in temozolomide-resistant MG.

Overview

The claims and statistics of this paper haven’t been checked yet.

Run the check — free, no account needed. It reads the open-access text and checks the sources it cites.

A few free checks a day · papers already verified open instantly · results are public

Integrity signals

Registry

Crossref · 10.1200/jco.2005.06.502

Cites

55 of 55 references verified0 citation errors · 0 not checkable

Statistics

Verification

Claims the paper makes

The claims and statistics of this paper haven’t been checked yet.

Run the check — free, no account needed. It reads the open-access text and checks the sources it cites.

A few free checks a day · papers already verified open instantly · results are public

Self-check

Percentages, sums and reported differences re-computed from the paper’s own numbers.

The self-check needs the paper’s full text.

Citations

Cites

Show all 55 references

Cited by

See all 288

Metadata

Authors
Quinn, J. A., Desjardins, A., Weingart, J., Brem, H., Dolan, M. E., Delaney, S. M., Vredenburgh, J., Rich, J., Friedman, A. H., Reardon, D. A., Sampson, J. H., Pegg, A. E., Moschel, R. C., Birch, R., McLendon, R. E., Provenzale, J. M., Gururangan, S., Dancey, J. E., Maxwell, J., Tourt-Uhlig, S., Herndon, J. E., Bigner, D. D., & Friedman, H. S.
Venue
Journal of Clinical Oncology
Published
2005-10-01
Volume
23
Issue
28
Pages
7178-7187
ISSN
  • 0732-183X (ISSN-L)
  • 1527-7755
OpenAlex
W2138545604
Cited by
288
References
55
FWCI
12.38
Type
journal article
Language
en
Open access
bronze

About these checks

Registry, retraction, Cites and statistics results are computed, not judged, with one exception: a printed reference that no index lists is read once by a model before it counts as a citation error. Claims are extracted by a model and kept only when their quote appears verbatim in the text; each cited source is then checked, with a model’s help, for whether it says what the claim relies on. Those verdicts can be wrong — read the claim’s quote and the cited source before relying on one.

Statistics and arithmetic are recomputed, not judged.

Confidence bands are shown only for fields calibrated on our annotated test set. None is calibrated yet, so no band is shown.

What counts as a claim ›How we measure confidence ›How we check this ›

Are you an author, or do you see a problem with this page? Request a review

How to cite

Cite CoChat for the checks on this page, and the paper for its own findings.

This page
CoChat. (2026). Citation check: Phase I Trial of Temozolomide Plus O6-Benzylguanine for Patients With Recurrent or Progressive Malignant Glioma. https://app.cochat.ai/papers/10.1200/jco.2005.06.502
The paper
Quinn, J. A., Desjardins, A., Weingart, J., Brem, H., Dolan, M. E., Delaney, S. M., Vredenburgh, J., Rich, J., Friedman, A. H., Reardon, D. A., Sampson, J. H., Pegg, A. E., Moschel, R. C., Birch, R., McLendon, R. E., Provenzale, J. M., Gururangan, S., Dancey, J. E., Maxwell, J., . . . Friedman, H. S. (2005). Phase I Trial of Temozolomide Plus O6-Benzylguanine for Patients With Recurrent or Progressive Malignant Glioma. Journal of Clinical Oncology. https://doi.org/10.1200/jco.2005.06.502

Data sources

Bibliographic data: Semantic Scholar, OpenAlex, Crossref.

Contains information from the Semantic Scholar Academic Graph Datasets, made available under the ODC Attribution License (ODC-BY 1.0).

Semantic Scholar’s data is described in: Kinney, R., et al. (2023). The Semantic Scholar Open Data Platform. arXiv:2301.10140.